Second phase of TB program that integrates HIV treatment begins in Harare, Zimbabwe

NewsGuard 100/100 Score

The second phase of the Integrated Health Care program to control tuberculosis has been implemented in Zimbabwe's capital of Harare, the Herald reports.

The program aims to integrate TB care with HIV/AIDS treatment, program coordinator Dorothy Nyoni said last week at an event aimed at educating people about the program.

According to Nyoni, the program will provide antiretroviral drugs to 170 people with HIV/TB coinfection who no longer are eligible to receive treatment from clinics. The program also will administer no-cost CD4+ T cell counts to people with HIV/TB coinfection. In addition, the program received a car to travel to Harare's Mabvuku and Tafara communities to provide TB treatment services to residents who otherwise would need to travel for treatment, Nyoni said. Harare TB Program Manager Clemence Duri praised the program but said the Mabvuku district has a shortage of TB nurses and is among the areas most affected by TB in Harare.

The program was coordinated by the Harare City Health Department and the International Union Against TB and Lung Disease and received funding from the European Union, the Herald reports (Herald, 9/8).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals increased risk of immune abnormalities in children of women with HIV